Results 21 to 30 of about 1,653 (153)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

Case Reports in Oncology, 2016
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative ...
Shao-Lun Lu, Feng-Ming Hsu, Kuan-Yu Chen, Chao-Chi Ho, James Chih-Hsin  Yang, Jason Chia-Hsien Cheng   +5 more
doaj   +2 more sources

Ablative radiotherapy in castration-resistant prostate cancer. [PDF]

BJU Int
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Hölscher T, Lohaus F, Koi L, Kotzerke J, Hoberück S, Thomas C, Borkowetz A, Löck S, Krause M, Troost EGC.   +9 more
europepmc   +2 more sources

Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

Clinical and Translational Radiation Oncology, 2022
Background: Management of Non-Small Cell Lung Cancer (NSCLC) patients with oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic Ablative Radiotherapy (SABR) targeting the oligoprogressive disease in ...
Houda Bahig, Marion Tonneau, Normand Blais, Philip Wong, Edith Filion, Marie-Pierre Campeau, Toni Vu, Afnan Al-Saleh, Mustapha Tehfé, Marie Florescu, David Roberge, Laura Masucci, Corentin Richard, Cynthia Menard, Bertrand Routy   +14 more
doaj   +1 more source

Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report. [PDF]

Thorac Cancer
Serial re‐biopsy in EGFR‐mutant NSCLC revealed sequential acquired EGFR T790M, MET c.3010C>G exon 14‐related alteration, and RET‐CCDC6 fusion. Mechanism‐guided therapy with almonertinib, almonertinib plus savolitinib, and later selpercatinib plus almonertinib with local radiotherapy achieved prolonged disease control, with survival approaching 50 ...
Zhu Y, Wang C, Hu NL, Wang DH, Wu SK.
europepmc   +2 more sources

A case of repeat oligoprogressive castration‐resistant prostate cancer treated with pulmonary metastasectomy

IJU Case Reports, 2023
Introduction Several retrospective studies have demonstrated the efficacy of progressive site‐directed therapy for oligoprogressive castration‐resistant prostate cancer.
Takahiko Soma, Soichiro Yoshida, Ryo Wakejima, Towako Taguchi, Shohei Fukuda, Hajime Tanaka, Minato Yokoyama, Kenichi Ohashi, Kenichi Okubo, Yasuhisa Fujii   +9 more
doaj   +1 more source

Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer

Prostate International, 2023
Background: In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention.
Taketo Kawai, Satoru Taguchi, Keina Nozaki, Naoki Kimura, Takahiro Oshina, Takuya Iwaki, Hotaka Matsui, Aya Niimi, Jun Kamei, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Tomoyuki Kaneko, Subaru Sawayanagi, Hidetsugu Nakayama, Ryogo Minamimoto, Hideomi Yamashita, Hideyo Miyazaki, Tetsuya Fujimura, Tohru Nakagawa, Haruki Kume   +21 more
doaj   +1 more source

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy

Thoracic Cancer, 2022
Highly active and durable systemic therapies such as targeted therapy and immunotherapy can convert widespread metastatic disease into oligometastatic status, for which metastasis‐directed local intervention can control and potentially prolong survival ...
Ho Young Lee, Sung Hyun Kim, Hong Yeul Lee, Young‐Min Lee, Ji Yeon Han, Heunglae Cho, Hyun‐Kyung Lee   +6 more
doaj   +1 more source

Metastasis-Directed Surgery for Solitary Pulmonary Metastasis After Pembrolizumab in Urothelial Carcinoma: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction The role of metastasis‐directed therapy in urothelial carcinoma remains uncertain, particularly in the immune checkpoint inhibitor era. We report a case of solitary pulmonary metastasis that developed after a favorable response to pembrolizumab and was managed with metastasectomy.
Takemura K, Tanaka M, Hamada Y, Karasaki T, Sakaguchi K, Uruga H, Urakami S, Fujimori S, Uchino K.   +8 more
europepmc   +2 more sources

Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple Myeloma. [PDF]

Hematol Oncol
ABSTRACT Radiotherapy (RT) constitutes an important treatment modality in multiple myeloma (MM), traditionally used for the management of symptomatic osteolytic and extramedullary lesions. Objectives of RT are symptom alleviation and prevention of complications such as neurological deficits and pathological fractures.
Schlusemann T, Shumilov E, Reinartz G, Steike DR, Lohmann S, Gravemeyer S, Stelljes M, Lenz G, Eich HT, Oertel M.   +9 more
europepmc   +2 more sources

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression

Diagnostics, 2023
Stereotactic ablative radiotherapy (SABR) may improve survival in patients with inoperable pulmonary oligometastases. However, the impact of pulmonary oligometastatic status after systemic therapy on SABR outcomes remains unclear.
Chin-Beng Ho, Jo-Ting Tsai, Chun-You Chen, Her-Shyong Shiah, Hsuan-Yu Chen, Lai-Lei Ting, Chia-Chun Kuo, I-Chun Lai, Hsin-Yi Lai, Chi-Li Chung, Kai-Ling Lee, Huey-En Tzeng, Kuen-Haur Lee, Hsin-Lun Lee, Shang-Wen Chen, Jeng-Fong Chiou   +15 more
doaj   +1 more source